Company Overview More
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
CEO: --
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > LGVN Longeveron > Detailed Quotes

LGVN Longeveron

21.900+2.320+11.85%
Close 12/08 07:56 ET
21.90000.00%
Post Mkt Price 12/08 07:57 ET
High
23.710
Open
19.580
Turnover
159.83M
Low
19.300
Prev.Close
19.580
Volume
7.33M
Market Cap
444.35M
P/E(TTM)
Loss
52Wk High
45.000
Shares
20.29M
P/E
Loss
52Wk Low
2.840
H Mkt Cap
88.60M
Bid-Ask Ratio
77.78%
Historical High
45.000
H Shares
4.05M
Vol. Ratio
0.67
Historical Low
2.840
Dividend TTM
--
Div Yield TTM
--
P/B
19.89
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
181.21%
Amplitude
22.52%
Avg Price
21.801
Min Trading Unit
1
Float Market Cap
88.60M
Bid-Ask Ratio
77.78%
Historical High
45.000
Float
4.05M
Vol. Ratio
0.67
Historical Low
2.840
Dividend TTM
--
P/B
19.89
Dividend LFY
--
Turnover Ratio
181.21%
Amplitude
22.52%
Avg Price
21.801
Min Trading Unit
1
Price Forecast

Loading...

News